Afuresertib - CAS 1047644-62-1
Catalog number: 1047644-62-1
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C18H17Cl2FN4OS
Molecular Weight:
427.32
COA:
Inquire
Targets:
Akt
Description:
Afuresertib, also known as GSK2110183,  is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor GSK2110183 binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.
Appearance:
Solid powder
Synonyms:
GSK-2110183; GSK 2110183; GSK2110183; GSK-2110183B; GSK 2110183B; GSK2110183B; Afuresertib.
MSDS:
Inquire
InChIKey:
AFJRDFWMXUECEW-LBPRGKRZSA-N
InChI:
InChI=1S/C18H17Cl2FN4OS/c1-25-16(14(19)9-23-25)13-7-15(27-17(13)20)18(26)24-12(8-22)6-10-3-2-4-11(21)5-10/h2-5,7,9,12H,6,8,22H2,1H3,(H,24,26)/t12-/m0/s1
Canonical SMILES:
CN1C(=C(C=N1)Cl)C2=C(SC(=C2)C(=O)NC(CC3=CC(=CC=C3)F)CN)Cl
Current Developer:
GlaxoSmithKline.
1.The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma.
Spencer A1, Yoon SS2, Harrison SJ3, Morris SR4, Smith DA4, Brigandi RA5, Gauvin J4, Kumar R5, Opalinska JB5, Chen C6. Blood. 2014 Oct 2;124(14):2190-5. doi: 10.1182/blood-2014-03-559963. Epub 2014 Jul 29.
The PI3K/AKT pathway is constitutively active in hematologic malignancies, providing proliferative and antiapoptotic signals and possibly contributing to drug resistance. We conducted an open-label phase 1 study to evaluate the maximum tolerated dose (MTD), safety, pharmacokinetics, and clinical activity of afuresertib-an oral AKT inhibitor-in patients with advanced hematologic malignancies. Seventy-three patients were treated at doses ranging from 25 to 150 mg per day. The MTD was established at 125 mg per day because of 2 dose-limiting toxicities in the 150-mg cohort (liver function test abnormalities). The most frequent adverse events were nausea (35.6%), diarrhea (32.9%), and dyspepsia (24.7%). Maximum plasma concentrations and area under the plasma concentration-time curves from time 0 to 24 hours were generally dose proportional at > 75-mg doses; the median time to peak plasma concentrations was 1.5 to 2.5 hours post dose, with a half-life of approximately 1.
2.Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Tolcher AW1, Patnaik A, Papadopoulos KP, Rasco DW, Becerra CR, Allred AJ, Orford K, Aktan G, Ferron-Brady G, Ibrahim N, Gauvin J, Motwani M, Cornfeld M. Cancer Chemother Pharmacol. 2015 Jan;75(1):183-9. doi: 10.1007/s00280-014-2615-5. Epub 2014 Nov 25.
PURPOSE: To identify the maximum tolerated dose (MTD) and recommended Phase II dose of MEK/AKT inhibitor combination of trametinib and afuresertib.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Akt Products


CAS 324029-01-8 AKTide-2T

AKTide-2T
(CAS: 324029-01-8)

AKTide-2T, a peptide substrate for Akt/PKB, has been found to act as an inhibitor and mimics the optimal phosphorylation sequence of Akt.

CAS 871361-88-5 SC66

SC66
(CAS: 871361-88-5)

SC66 is a novel and potent AKT inhibitor, which reduced cell viability in a dose- and time-dependent manner, inhibited colony formation and induced apoptosis in...

CAS 1396257-94-5 GDC-0068 dihydrochloride

GDC-0068 dihydrochloride
(CAS: 1396257-94-5)

Testing against a broad panel of 230 kinases, GDC-0068 only inhibits 3 kinases by >70% at 1 μM concentration (PRKG1α, PRKG1β, and p70S6K, with IC50 of 98 nM, 69...

CAS 1001264-89-6 Ipatasertib

Ipatasertib
(CAS: 1001264-89-6)

Ipatasertib, also known as GDC-0068 is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplas...

CAS 902779-59-3 FPA 124

FPA 124
(CAS: 902779-59-3)

FPA 124 is an Akt/PKB inhibitor (IC50 = 100 nM) that inhibits cell proliferation in various cancer cell lines in vitro and decreases NF-κB activity and tumor lo...

CAS 552325-16-3 A-443654

A-443654
(CAS: 552325-16-3)

A-443654 is a potent small-molecule inhibitor of all three Akt serine/threonine kinases, induces Akt Ser-473 phosphorylation in all human cancer cell lines test...

CAS 1032349-93-1 MK-2206

MK-2206
(CAS: 1032349-93-1)

MK-2206 is an allosteric inhibitor of Akt that prevents translocation of Akt to membranes. It is also an orally bioavailable allosteric inhibitor of the serine/...

CAS 893422-47-4 Akt1 and Akt2-IN-1

Akt1 and Akt2-IN-1
(CAS: 893422-47-4)

Akt1 and Akt2-IN-1 is an allosteric inhibitor of Akt1 and Akt2 with the IC50 of 3.5 nM and 42 nM respectively. It has potent and balanced activity. It is depend...

Chemical Structure

CAS 1047644-62-1 Afuresertib

Quick Inquiry

Verification code

Featured Items